Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.
Chamberlain, S.D., Redman, A.M., Wilson, J.W., Deanda, F., Shotwell, J.B., Gerding, R., Lei, H., Yang, B., Stevens, K.L., Hassell, A.M., Shewchuk, L.M., Leesnitzer, M.A., Smith, J.L., Sabbatini, P., Atkins, C., Groy, A., Rowand, J.L., Kumar, R., Mook, R.A., Moorthy, G., Patnaik, S.(2009) Bioorg Med Chem Lett 19: 360-364
- PubMed: 19071018 
- DOI: https://doi.org/10.1016/j.bmcl.2008.11.077
- Primary Citation of Related Structures:  
3EKN, 3ELJ - PubMed Abstract: 
The SAR of C5' functional groups with terminal basic amines at the C6 aniline of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines is reported. Examples demonstrate potent inhibition of IGF-1R with 1000-fold selectivity over JNK1 and 3 in enzymatic assays.
Organizational Affiliation: 
GlaxoSmithKline, Oncology R&D, 5 Moore Drive, Research Triangle Park, NC 27709, USA.